" class="no-js "lang="en-US"> Orexo - Medtech Alert
Friday, August 29, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Orexo | Pharmtech Focus

Orexo

About Orexo

Orexo

Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs mainly within the growing space of mental illness and substance use disorder. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product ZUBSOLV® for treatment of opioid use disorder. Total net sales for 2019 amounted to SEK 845 million and the number of employees was 127. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.

For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.

Related Story

Drug Development

 Orexo Shares New Timeline for the High-Dose Rescue Medication for Opioid Overdose, OX124 | MTA

Orexo Shares New Timeline for the High-Dose Rescue Medication for Opioid Overdose, OX124

April 3 2023

Orexo today announces the expected US launch of OX124, a high-dose rescue medication for opioid overdose, […]

Clinical Trials

 Orexo’s Nasal Adrenaline Rescue Medication OX640 Enters Clinical Development | Pharmtech Focus

Orexo’s Nasal Adrenaline Rescue Medication OX640 Enters Clinical Development

July 5 2022

Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces it has successfully initiated the first explorative human clinical study […]

Appointments

 Orexo Appoints Fredrik Järrsten as New CFO | Pharmtech Focus

Orexo Appoints Fredrik Järrsten as New CFO

March 11 2022

Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announces today that the company has appointed Fredrik Järrsten as […]

Drug Development

 Orexo Provides Information About its New Proprietary Drug Delivery Platform - AmorphOXTM | Pharmtech Focus

Orexo Provides Information About its New Proprietary Drug Delivery Platform - AmorphOXTM

November 26 2021

Orexo AB (publ.),(STO:ORX) (OTCQX:ORXOY) today provides information about its new proprietary drug delivery platform, amorphOXTM, a […]